2015-03-23 08:12 ET – News Release (Marketwired)
INMED RECEIVES EXEMPTION STATUS FROM HEALTH CANADA
InMed Pharmaceuticals Inc. (CSE:IN, OTCQB:IMLFF) has received a notice from Health Canada dated March 12, 2015, approving InMed’s application for an exemption under Section 56 of the Controlled Drugs and Substances Act.
This exemption allows InMed to use a specified quantity of selected cannabinoid compounds including Delta 9 tetrahydrocannabinol and cannabidiol. Importantly this exemption allows InMed to possess the controlled substances and to administer them for research and development purposes, which include in vitro studies as well as the use of these compounds in animal models of human diseases.
Craig Schneider, president and chief executive officer, states, “Obtaining this exemption is a critical milestone for InMed as we prepare for human clinical studies for our lead programs in glaucoma (CTI-085) and arthritis (CTI-091) moving towards the clinical development of their respective proprietary delivery systems.”
The Office of Controlled Substances’ licensed dealer has also been notified so that it may import the controlled substances on behalf of InMed.
About InMed
InMed is a clinical stage biopharmaceutical company that specializes in developing cannabis based therapies through the research and development into the extensive pharmacology of cannabinoids coupled with innovative drug delivery systems. InMed’s proprietary platform technology, product pipeline and accelerated development pathway are the fundamental value drivers of the company.
We Seek Safe Harbor